Upstream Bio, Inc. stock analysis
Want to see UPB full AI Analyst Report?
Upstream Bio, Inc. (UPB) Stock Price & Analysis
UPB Stock Chart & Stats
- Day’s Range
- $2.73 - $2.98
- 52-Week Range
- $2.68 - $33.68
- Previous Close
- $2.86
- Volume
- N/A
- Average Volume (3M)
- 1.32M
- Market Cap
- $152.38M
- Enterprise Value
- $82.13M
- Total Cash (Recent Filing)
- $207.37M
- Total Debt (Recent Filing)
- $789.00K
- Price to Earnings (P/E)
- ―
- Beta
- 1.25
- Next Earnings
- Mar 17, 2027 (Est.)
- EPS Estimate
- -0.7
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive Equity
Minimal debt and solid positive equity provide financial flexibility relative to many development-stage biotechs. This structure reduces near-term interest and refinancing pressure, while preserving capacity to direct capital toward clinical development, although ongoing losses can still erode that support.
Defined Phase 3 Clinical Path
A defined pivotal-trial plan gives verekitug a clearer regulatory and development pathway than an earlier-stage program. Starting two placebo-controlled studies across important respiratory indications could create meaningful future product optionality if efficacy and safety are confirmed.
High Gross Margin Potential
The exceptionally high reported gross margin indicates that revenue generated to date carries substantial margin before operating expenses. If verekitug or other candidates eventually produce commercial sales, this economics profile could support attractive contribution margins, subject to successful development and launch.
Bears Say
Large And Rising Cash Burn
Heavy operating and free-cash-flow deficits show that UPB is not self-funding and must continue financing development externally. If the burn persists or rises, available resources may be depleted faster, increasing funding needs and limiting flexibility across the clinical program.
Deepening Losses And Minimal Revenue
Very small, declining revenue provides little offset to a large and expanding cost base, leaving UPB deeply unprofitable. This weak operating foundation extends the path to self-sustaining earnings and makes future financial performance highly dependent on clinical progress and eventual commercialization.
Clinical Execution And Trial Risk
The pivotal program remains exposed to execution, efficacy, safety, enrollment, and regulatory risks before it can support a commercial product. Failure to reproduce Phase 2 results or delays in the large Phase 3 studies could materially postpone revenue and increase funding requirements.
Upstream Bio, Inc. News
Upstream Pharma Earns Buy Rating as Verekitug’s Differentiated TSLP Strategy Advances Into Pivotal Phase III for Severe Asthma and CRSwNP
William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on September 2. Matt Phipps has given his Buy rating due to a
FDA-Supported Streamlined Phase 3 Program and Strong Long-Term Asthma Upside Underpin Buy Rating with Unchanged $19 Price Target
Kate Dellorusso, an analyst from LifeSci Capital, maintained the Buy rating on Upstream Bio, Inc.. The associated price target remains the same with $19.00. Kate Dellorusso has given his Buy
UPB FAQ
What was Upstream Bio, Inc.’s price range in the past 12 months?
What is Upstream Bio, Inc.’s market cap?
When is Upstream Bio, Inc.’s upcoming earnings report date?
How were Upstream Bio, Inc.’s earnings last quarter?
Is Upstream Bio, Inc. overvalued?
Does Upstream Bio, Inc. pay dividends?
What is Upstream Bio, Inc.’s EPS estimate?
How many shares outstanding does Upstream Bio, Inc. have?
What happened to Upstream Bio, Inc.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Upstream Bio, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Upstream Bio, Inc. Stock Smart Score
Company Description
Upstream Bio, Inc.
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
- Sector
- General
- Industry
- Biotechnology
- CEO
- E. Rand Sutherland
- Employees
- 75
- Website
- upstreambio.com
- Address
- 890 Winter Street, Waltham, MA, 02451, US
Upstream Bio, Inc. (UPB) Earnings & Revenues
UPB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |









